New drug combo shows promise for Tough-to-Treat blood cancers

NCT ID NCT02500407

Completed Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to treatment. The goal is to find the best dose and check safety and effectiveness. About 713 adults are taking part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mosunetuzumab (with or without atezolizumab)
What this could lead to: If successful, this could offer a new treatment option for people with certain blood cancers that have not responded to prior therapies.
What could go wrong: This is an early-phase trial, so safety and effectiveness are not yet proven. Side effects may occur, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOCYTIC LEUKEMIA, CHRONIC LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

Barts Cancer Institute

London, EC1A 7BE, United Kingdom
Clínica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Complejo Asistencial Universitario de Salamanca

Salamanca, 37007, Spain
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Hospital Universitario La Paz

Madrid, 280146, Spain
Hospital Universitario Vall d Hebron

Barcelona, 08035, Spain
Icon Cancer Care South Brisbane

South Brisbane, Queensland, 4101, Australia
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Klinikum der Universität München, Campus Großhadern

München, 83177, Germany
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center - Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Cancer Center at Westchester

Harrison, New York, 10604, United States
Monash Health Clinical Trial Pharmacy department

Clayton, Victoria, 3168, Australia
New York Uni Medical Center

New York, New York, 10016, United States
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Rocky Mountain Cancer Center

Denver, Colorado, 80218, United States
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal Hobart Hospital

Hobart, Tasmania, 7000, Australia
Royal Marsden Hospital;Institute of Cancer Research

Sutton, SM2 5PT, United Kingdom
Samsung Medical Center

Seoul, 06351, South Korea
Sansum Medical Clinic, Inc.

Santa Barbara, California, 93105, United States
Seoul National University Hospital

Seoul, 03080, South Korea
St Vincent's Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
St. Vincent's Hospital Melbourne

Fitzroy, South Australia, 3065, Australia
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The Perth Blood Institute

Nedlands, Western Australia, 6009, Australia
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, 55101, Germany
Universitatsklinikum Koln

Cologne, 50931, Germany
University of California San Diego Moores Cancer Center

La Jolla, California, 92093-0698, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19103, United States
Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany
Willamette Valley Cancer Insitute and Research Center

Springfield, Oregon, 97477, United States
Yale University School Of Medicine

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.